HUTCHMED (China) Limited (HCM) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome everyone. Thank you for joining Hachmed 2026 interim results announcement and presentation. Before we start, I would just like to go over the safe harbors statement and disclaimer on page two. The performance and results of operation of Hachmed Group contained within this presentation are historical in nature and past performance is no guarantee of future results. Next, I would like to invite our Acting CEO and CFO, Johnny Chan, to start the opening. Johnny? Okay, thank you, David. And welcome everyone again, joining our interim results webcast tonight. Together with me, we have our Deputy CFO, Lorenzo Zhou, also our George Yuan, Head of Commercial and also our Dr. Dai, Head of Discovery and Global Portfolio Management. All of us will be sharing with you our first half results and outlook. So on page four, as you can all see, we have achieved a lot in the first half. China product sales have very strong results, especially Elinate and Solenda, which grew by over 40%. Fusecla global in-market sales were strong, Ex-US markets were up 70% after rapid geographic expansion. On the bottom left, we have received two approved label expansions. Fluquitinib for RCC and Savolitinib for GC. In addition, we have three NDAs in China under priority review. On the top right, our next wave of innovation focuses on ATTCs. We have two first-in-class assets which have entered the Phase 1 clinical trials. A third asset, HMPL830, has cleared its IND and will be entering the clinic in the second half. At the same time, the Global Cephron Study and the China Sanovo Study will have their data readouts in the second half. I will now hand it over to Lorenzo Zhou, our Deputy CFO, to discuss our financial results. Thank you, Johnny. On slide number six, I'd like to give more details of o...